Analyst Pick Tel-Instrument Electronics Corp. (NYSE-MKT: TIK) Profiled by Large Media Groups and four brief reports
June 17 2015 - 07:00AM
InvestorsHub NewsWire
NEW YORK, NY -- June 17, 2015 -- InvestorsHub NewsWire
-- Small Cap Profit makes the connection between sophisticated
investors and high quality micro and small cap companies that are
currently undervalued. We are an issuer of reports written by
experienced financial analysts and who provide a straight forward
assessment of a profiled company. They include stocks traded in the
NYSE, NASDAQ, and OTCBB exchanges.
*Special Analyst
Profile*
Tel-Instrument Electronics Corp. (NYSE-MKT: TIK) Company
Highlights:
- -Analyst gives 100% price target from current price.
-Strong competitive position in next generation Mode 5 flight-line
test sets. Mode 5 is the next generation of the IFF (Identification
Friend or Foe) system used by the Air Traffic Control System to
identify and track military aircraft.
-Significant regulatory, IP, and financial barriers to entry in
core markets.
-Multi-year projected revenue and profit growth driven by roll out
of Mode 5 products.
-$33 million in shippable backlog as of December 31, 2014, with
large amount of expected follow – on sole source orders.
-Diverse customer base with long-term relationships.
An analyst report on TIK that includes a brief company overview,
technology solutions, financial review, analyst summary, valuation,
and recommendation can be viewed by using the following link at no
cost and no email entry.
http://bit.ly/__TIK_AnalystReport
Or if you would like to receive profiles quicker you can text
"Profits" to 25827
4 Brief Reports:
Capstone Turbine Corp. (NASDAQ: CPST) is a producer of low-emission
microturbine systems. Capstone Turbine has shipped over 8,500
Capstone Microturbine systems to customers worldwide. The company's
systems have logged millions of documented runtime operating hours.
Capstone Turbine is a member of the U.S. Environmental Protection
Agency's Combined Heat and Power Partnership.
CPST has released its fourth quarter and year-end financial
results. You can read a full summary in the report located at this
link: http://bit.ly/_CPST_AnalystBrief
Galena Biopharma, Inc. (NASDAQ: GALE) is a biopharmaceutical
company developing and commercializing, targeted oncology
therapeutics across the full spectrum of cancer care. Galena's
development portfolio ranges from mid- to late-stage clinical
assets, including a robust immunotherapy program led by NeuVax™
(nelipepimut-S) currently in an international, Phase 3 clinical
trial.
Analyst brief can be found here: http://bit.ly/_GALE_AnalystBrief
Apple, Inc. (NASDAQ: AAPL) designs, manufactures, and markets
mobile communication and media devices, personal computers,
watches, and portable digital music players worldwide.
Apple Pay has kicked off a new era in online payments and there are
a plethora of articles on the subject. Read AAPL’s comments on
their growing payment application in the report that follows:
http://bit.ly/_AAPL_AnalystBrief
22nd Century Group, Inc. (NYSE MKT: XXII) is a plant biotechnology
company focused on technology which allows it to increase or
decrease the level of nicotine in tobacco plants through genetic
engineering and plant breeding. 22nd Century owns or exclusively
controls 128 issued patents and 52 pending patent applications in
96 countries.
XXII has obtained licensing in New York giving them the ability to
distribute product throughout the state. Read about the new
licenses as well as information about a completed, direct stock
offering in this report: http://bit.ly/_XXII__AnalystBrief
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and is subject to the Safe Harbor created by those
sections. This material contains statements about expected future
events and/or financial results that are forward-looking in nature
and subject to risks and uncertainties. Such forward- looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of mentioned company to be materially different from
the statements made herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis
by a 3rd party research analyst. However, we are only human and may
make mistakes. This report was prepared for informational purposes
only. A full disclaimer can be found by viewing the full
analyst report. We do not engage in high frequency trading or hold
any positions of profiled company.
For more information and services provided beyond this release
please use contact information provided below. If you notice any
errors or omissions, please notify us below.
If you wish to have a company covered in more detail by our team,
or wish to learn more about our services, please contact us at
editor@smallcapprofit.com. For any urgent concerns or inquiries
please contact us.
Source: Small Cap Profit
Contact: editor@smallcapprofit.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Feb 2024 to Mar 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2023 to Mar 2024